Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Glioblastoma × Standard of Care × Clear all

Phase

Phase NA 2 Phase 2 2 Phase EARLY_PHASE1 1 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 7 Breast Neoplasms 7 Lung Neoplasms 5 Head and Neck Neoplasms 5 Neoplasms 4 Leukemia, Myeloid, Acute 4 Hematologic Neoplasms 3 Colorectal Neoplasms 3 Recurrence 2 Pulmonary Disease, Chronic Obstructive 2 Neoplasm Metastasis 2 Leukemia 2 Colonic Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Xerostomia 1 Urologic Neoplasms 1 Urologic Diseases 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Urinary Bladder Diseases 1 Teratoma 1 Stroke 1 Stomatitis 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Sarcoma 1 Rectal Neoplasms 1 Radiation Injuries 1 Prostatic Diseases 1

Interventions

Temozolomide 37 Radiotherapy 17 Lomustine 11 Bevacizumab 10 Carmustine 8 Radiation 7 Procarbazine 4 Surgical Procedures, Operative 3 Magnetic Resonance Spectroscopy 3 pembrolizumab 2 depatuxizumab mafodotin 2 Tf-CRM107 2 Radiotherapy, Intensity-Modulated 2 Drug Therapy 2 Dihematoporphyrin Ether 2 DNA Methylation 2 Carboplatin 2 ABT-414 2 trans-sodium crocetinate 1 tofacitinib 1 sargramostim 1 rindopepimut 1 niraparib 1 marizomib 1 edotecarin 1 contrast agent BR1 1 cediranib 1 carmustine, poliferprosan 20 drug combination 1 Vincristine 1 Valproic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03393000 2021-07-22

INTACT

Diffusion Pharmaceuticals Inc

Phase 3 Terminated

19 enrolled 8 charts

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡